|Sponsor||Study Title||Reference in Clinicaltrials.gov (if relevant)||Description||Phase||Type||Condition/Diagnosis||Citation|
|Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands||https://clinicaltrials.gov/ct2/show/NCT01273597"||Kidney Failure, Chronic||Observational||Clinical Trial||This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands. Participants will be followed for 6 months. Data will be collected from participants initiated on Zemplar therapy according to standard of care. The time to achieving the maintenance dose of Zemplar (paricalcitol injection), the proportion of participants achieving target parathyroid hormone levels, and prevalence of elevated serum calcium and phosphate levels will be evaluated.|
|A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH||https://clinicaltrials.gov/ct2/show/NCT02264639||Paroxysmal Nocturnal Hemoglobinuria (PNH)||Phase 1||Clinical Trial||This study will be the initial exploration of APL-2 in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of APL-2 will guide decisions to further develop the drug.|
|CorRELation Between PatIent PErception and Findings on Clinical Examination (RELIEF)||https://clinicaltrials.gov/ct2/show/NCT01627743||Chronic Obstructive Pulmonary Disease (COPD)||Observational||Clinical Trial||This is a multi-center, prospective, non-interventional study that aims to evaluate in daily clinical practice, the possible corelation between patIent perception of the ability to perform morning activities and physician evaluation; patients with COPD, grade C and D.||Yavor Ivanov; Ognian Georgiev; Hodzhev Vladimir; Petkova Diana; Petkova Daniela; Staneva Marina; Mineva Petya: Yavor Ivanov1; Ognian Georgiev2; Hodzhev Vladimir3; Petkova Diana4; Petkova Daniela2; Staneva Marina5; Mineva Petya5
2nd International Workshop on Lung Health. COPD: New Challenges, New Solutions Valencia, 19-21 February 2015
|ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice||https://clinicaltrials.gov/ct2/show/NCT01388166||Pulmonary Disease, Chronic Obstructive||Observational||Clinical Trial||The objective of this observational study is to collect and evaluate data on medication adherence of patients on maintenance COPD therapy with long-acting anticholinergic (e.g. Spiriva® delivered by HandiHaler® or Respimat®) using the MMAS-8 questionnaire.||http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview/205/205_483.html|
|A Randomised, Double-blind, Placebo-Controlled, Single-Ascending Dose and Multiple Dose Phase I Study to Assess the Safety, Pharmacokinetics and Effect of Food on Orally Administered DS107G in Healthy Subjects||https://clinicaltrials.gov/ct2/show/NCT02673593||Healthy Volunteers||Phase 1||Clinical Trial||The purpose of the study is to investigate the safety, pharmacokinetics and food effect of DS102 (up to 2000mg single and multiple daily doses) and placebo in healthy participants. DS102 capsules will be orally administered for up to 4 weeks, and will be compared against placebo.||Derks M, Anzures-Cabrera J, Turnbull L, Phelan M.: Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Clin Drug Investig. 2011;31(5):325-35. doi: 10.2165/11533550-000000000-00000.
|Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)||https://clinicaltrials.gov/ct2/show/NCT00882414||Thrombocytosis Iron-Deficiency Anemia||Phase II||Clinical Trial||The aim of this study is to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.||Stefanie Kulnigg-Dabsch, Rayko Evstatiev, Clemens Dejaco, Christoph Gasche: Effect of Iron Therapy on Platelet Counts in Patients with Inflammatory Bowel Disease-Associated Anemia
PLoS ONE | www.plosone.org April 2012 | Volume 7 | Issue 4 | e34520